146 related articles for article (PubMed ID: 36639836)
21. Low acyl-CoA synthetase 5 expression in colorectal carcinomas is prognostic for early tumour recurrence.
Hartmann F; Sparla D; Tute E; Tamm M; Schneider U; Jeon MK; Kasperk R; Gassler N; Kaemmerer E
Pathol Res Pract; 2017 Mar; 213(3):261-266. PubMed ID: 28153554
[TBL] [Abstract][Full Text] [Related]
22. Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein.
Murugesan G; Fox PL
J Clin Invest; 1996 Jun; 97(12):2736-44. PubMed ID: 8675684
[TBL] [Abstract][Full Text] [Related]
23. Evidence for two distinct lysophospholipase activities that degrade lysophosphatidylcholine and lysophosphatidic acid in neuronal nuclei of cerebral cortex.
Baker RR; Chang HY
Biochim Biophys Acta; 1999 May; 1438(2):253-63. PubMed ID: 10320808
[TBL] [Abstract][Full Text] [Related]
24. Targeting of Acyl-CoA synthetase 5 decreases jejunal fatty acid activation with no effect on dietary long-chain fatty acid absorption.
Meller N; Morgan ME; Wong WP; Altemus JB; Sehayek E
Lipids Health Dis; 2013 Jun; 12():88. PubMed ID: 23767941
[TBL] [Abstract][Full Text] [Related]
25. TP53 status regulates ACSL5-induced expression of mitochondrial mortalin in enterocytes and colorectal adenocarcinomas.
Klaus C; Kaemmerer E; Reinartz A; Schneider U; Plum P; Jeon MK; Hose J; Hartmann F; Schnölzer M; Wagner N; Kopitz J; Gassler N
Cell Tissue Res; 2014 Jul; 357(1):267-78. PubMed ID: 24770931
[TBL] [Abstract][Full Text] [Related]
26. Intestinal acyl-CoA synthetase 5: activation of long chain fatty acids and behind.
Klaus C; Jeon MK; Kaemmerer E; Gassler N
World J Gastroenterol; 2013 Nov; 19(42):7369-73. PubMed ID: 24259967
[TBL] [Abstract][Full Text] [Related]
27. Effects of lysophosphatidylcholine on monolayer cell permeability of human coronary artery endothelial cells.
Yan S; Chai H; Wang H; Yang H; Nan B; Yao Q; Chen C
Surgery; 2005 Sep; 138(3):464-73. PubMed ID: 16213900
[TBL] [Abstract][Full Text] [Related]
28. Modulating effects of acyl-CoA synthetase 5-derived mitochondrial Wnt2B palmitoylation on intestinal Wnt activity.
Klaus C; Schneider U; Hedberg C; Schütz AK; Bernhagen J; Waldmann H; Gassler N; Kaemmerer E
World J Gastroenterol; 2014 Oct; 20(40):14855-64. PubMed ID: 25356045
[TBL] [Abstract][Full Text] [Related]
29. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism.
Takahashi M; Okazaki H; Ogata Y; Takeuchi K; Ikeda U; Shimada K
Atherosclerosis; 2002 Apr; 161(2):387-94. PubMed ID: 11888522
[TBL] [Abstract][Full Text] [Related]
30. Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition.
Li LO; Ellis JM; Paich HA; Wang S; Gong N; Altshuller G; Thresher RJ; Koves TR; Watkins SM; Muoio DM; Cline GW; Shulman GI; Coleman RA
J Biol Chem; 2009 Oct; 284(41):27816-27826. PubMed ID: 19648649
[TBL] [Abstract][Full Text] [Related]
31. A splice variant in the ACSL5 gene relates migraine with fatty acid activation in mitochondria.
Matesanz F; Fedetz M; Barrionuevo C; Karaky M; Catalá-Rabasa A; Potenciano V; Bello-Morales R; López-Guerrero JA; Alcina A
Eur J Hum Genet; 2016 Nov; 24(11):1572-1577. PubMed ID: 27189022
[TBL] [Abstract][Full Text] [Related]
32. Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation.
Hou T; Tian Y; Cao Z; Zhang J; Feng T; Tao W; Sun H; Wen H; Lu X; Zhu Q; Li M; Lu X; Liu B; Zhao Y; Yang Y; Zhu WG
Mol Cell; 2022 Nov; 82(21):4099-4115.e9. PubMed ID: 36208627
[TBL] [Abstract][Full Text] [Related]
33. ACSL family: The regulatory mechanisms and therapeutic implications in cancer.
Quan J; Bode AM; Luo X
Eur J Pharmacol; 2021 Oct; 909():174397. PubMed ID: 34332918
[TBL] [Abstract][Full Text] [Related]
34. Targeting Long Chain Acyl-CoA Synthetases for Cancer Therapy.
Rossi Sebastiano M; Konstantinidou G
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31344914
[TBL] [Abstract][Full Text] [Related]
35. Impact of lysophosphatidylcholine on the plasminogen activator system in cultured vascular smooth muscle cells.
Yoon BK; Kang YH; Oh WJ; Park K; Lee DY; Choi D; Kim DK; Lee Y; Rhyu MR
J Korean Med Sci; 2012 Jul; 27(7):803-10. PubMed ID: 22787379
[TBL] [Abstract][Full Text] [Related]
36. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients.
Okita M; Gaudette DC; Mills GB; Holub BJ
Int J Cancer; 1997 Mar; 71(1):31-4. PubMed ID: 9096662
[TBL] [Abstract][Full Text] [Related]
37. Long-chain acyl-CoA synthetase 6 regulates lipid synthesis and mitochondrial oxidative capacity in human and rat skeletal muscle.
Teodoro BG; Sampaio IH; Bomfim LH; Queiroz AL; Silveira LR; Souza AO; Fernandes AM; Eberlin MN; Huang TY; Zheng D; Neufer PD; Cortright RN; Alberici LC
J Physiol; 2017 Feb; 595(3):677-693. PubMed ID: 27647415
[TBL] [Abstract][Full Text] [Related]
38. Fatty acid transport by vectorial acylation in mammals: roles played by different isoforms of rat long-chain acyl-CoA synthetases.
Tong F; Black PN; Coleman RA; DiRusso CC
Arch Biochem Biophys; 2006 Mar; 447(1):46-52. PubMed ID: 16466685
[TBL] [Abstract][Full Text] [Related]
39. Lysophosphatidylcholine inhibits insulin-induced Akt activation through protein kinase C-alpha in vascular smooth muscle cells.
Motley ED; Kabir SM; Gardner CD; Eguchi K; Frank GD; Kuroki T; Ohba M; Yamakawa T; Eguchi S
Hypertension; 2002 Feb; 39(2 Pt 2):508-12. PubMed ID: 11882599
[TBL] [Abstract][Full Text] [Related]
40. Long-Chain Acyl-CoA Synthetase 4-Mediated Fatty Acid Metabolism Sustains Androgen Receptor Pathway-Independent Prostate Cancer.
Ma Y; Zhang X; Alsaidan OA; Yang X; Sulejmani E; Zha J; Beharry Z; Huang H; Bartlett M; Lewis Z; Cai H
Mol Cancer Res; 2021 Jan; 19(1):124-135. PubMed ID: 33077484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
